We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ablynx NV ADS (delisted) | NASDAQ:ABLX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 52.87 | 24.00 | 68.00 | 0 | 01:00:00 |
From Jun 2019 to Jun 2024
By Donato Paolo Mancini
Sanofi SA (SAN.FR) and Ablynx NV (ABLX.BT) said Monday that the initial tender offer period for the acquisition of Ablynx has successfully closed, and that a squeeze-out tender period will begin later this month.
The French drug company said it will own 95.60% of the outstanding shares of Ablynx on the settlement date of the offers, and confirmed the minimum tender condition had been satisfied.
Sanofi said a squeeze-out for the Ablynx securities not tendered to the offers will begin on May 22 and expire on June 12. Upon completion of the squeeze-out, all securities of Ablynx will be delisted.
Sanofi said last January it would acquire nanobody-focused company Ablynx for 3.9 billion euros ($4.7 billion) in a deal aimed at expanding its rare blood disorders franchise.
Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com
(END) Dow Jones Newswires
May 14, 2018 02:42 ET (06:42 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Ablynx NV Chart |
1 Month Ablynx NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
